Combined Lorlatinib, Dabrafenib, and Trametinib Treatment for ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer with a Lorlatinib-Induced BRAF V600E Mutation: A Case Report
Dan Li(Hebei Medical University), Yudong Wang(Shanxi University), Long Wang(The University of Texas at San Antonio Health Science Center), Jiayin Liu(Hebei Medical University), Feng Li(Bengbu Medical College), Zhisong Fan(Hebei Medical University), Jing Zuo(Hebei Medical University), Hui Jin(University of Electronic Science and Technology of China), Jing Han(Hebei Medical University), Xue Zhang(Hebei Medical University)
Cited by 5
Related Papers
Dual Antiplatelet Therapy vs Alteplase for Patients With Minor Nondisabling Acute Ischemic Stroke
|JAMA|2023|209
Hepatitis due to Reactivation of Hepatitis B Virus in Endemic Areas Among Patients With Hepatitis C Treated With Direct-acting Antiviral Agents
|Clinical Gastroenterology and Hepatology|2016|197
Effect of Remote Ischemic Conditioning vs Usual Care on Neurologic Function in Patients With Acute Moderate Ischemic Stroke
|JAMA|2022|185
Stretchable Energy‐Harvesting Tactile Interactive Interface with Liquid‐Metal‐Nanoparticle‐Based Electrodes
|Advanced Functional Materials|2020|167